retatrutide weight loss trial data VisualAbstract: reduces body by 17.5% in patients with obesity 🚨 TRIUMPH-1: #retatrutide topline data🚨

The FDAs prior warnings regarding the potential elevated risk of medullary thyroid carcinoma associated with GLP-1 RAs may encourage more patients on GLP-1 RA therapy to undergo thyroid ultrasounds, thereby enhancing tumor detection

A 2024 review published in Circulation found that 20 to 50 percent of the total weight loss achieved on GLP-1 receptor agonists comes from lean muscle mass not fat tissue. The landmark STEP 1 trial data confirmed this, showing lean mass reduction of 6.92 kg in patients losing an average of 15.3 kg meaning approximately 45 percent of that weight was not fat at all, but metabolically active muscle. This distinction is not a minor footnote

In the SURPASS-2 trial, the active ingredient in Zepbound medication was found to be superior to semaglutide in regards to the mean change in the glycated hemoglobin level with the added effect of weight reduction

pylori infection Helicobacter pylori (H

All patients receive a sterile vial not prefilled syringes for safety, proper dosing, and the best shelf life